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Abstract
Background: The Centers for Disease Control and Prevention (CDC) and the United States Preventive Services Task
Force (USPSTF) recently augmented risk-based hepatitis C (HCV) screening guidelines with a recommendation to
perform one-time screening in all persons born during 1945 – 1965, a birth cohort known to have a higher
prevalence of HCV. We sought to estimate the proportion of veterans seen at the Atlanta VA Medical Center
(AVAMC) who had ever been screened for HCV infection by birth year.
Methods: We used an administrative database of all veterans seen at the AVAMC between January 1, 2011 and
December 31, 2011, and a laboratory generated list of all HCV antibody tests and HCV RNA viral loads that were
performed at the AVAMC to determine receipt of screening and HCV antibody positivity. Odds ratios and 95%
confidence intervals were estimated using SAS version 9.2 (SAS institute, Cary, North Carolina).
Results: HCV antibody testing had ever been performed on 48% (41,556) of the veterans seen in 2011; 10% of
those tested had a positive antibody. Confirmatory viral loads were performed in 96% of those with a positive
antibody screen. Those born during 1945 – 1965 were more likely to have a HCV antibody performed when
compared with those born in other years (54% vs. 41%, odds ratio [OR] 1.70, 95% Confidence Interval [CI] 1.65-1.74).
Among veterans ever tested for HCV antibody (n = 41,556), those born during 1945 – 1965 were 6 times more likely
to have a positive HCV antibody (15% vs. 3%, OR 5.87, 95% CI 5.32-6.78), and 3 times more likely to have chronic
HCV infection (76% vs. 50%, OR 3.25, 95% CI 2.65-4.00).
Conclusions: Nearly half of the veterans seen in 2011 at the AVAMC had ever been tested for HCV infection. When
examined by birth cohort, over half of the veterans born during 1945 – 1965 had been screened for HCV and 15%
of those screened had a positive HCV antibody. Our findings confirm the increased prevalence of HCV infection in
persons born during 1945 – 1965 as identified in the updated CDC and USPSTF recommendations.
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Background
In 1990, serologic tests that detect antibodies to the
hepatitis C virus (HCV) became commercially available
in the United States. The Centers for Disease Control
and Prevention (CDC) published guidelines on screen-
ing blood donors for HCV infection in 1991 and recom-
mendations for HCV screening in persons with high
risk behaviors in 1998 [1,2] (Figure 1). The US Veterans
Health Administration (VHA) implemented HCV screen-
ing guidelines in 2001 that not only recommended screen-
ing veterans with the risk factors described in the CDC
guidelines, but also screening any veteran with immoder-
ate use of alcohol, a history of tattoos or repeated body
piercing, intranasal cocaine use, multiple sexual partners,
or Vietnam-era military service (i.e. dates of active military
service between August 5, 1964 and May 7, 1975) [3]. In
2002, VHA introduced an electronic clinical reminder for
HCV screening. In August 2012, CDC augmented risk-
based HCV screening guidelines with a recommendation
to perform one-time HCV screening in all persons born
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during 1945 – 1965, a birth cohort known to have a
higher risk of having HCV infection [4,5]. In guidance
published in June 2013, the United States Preventive
Services Task Force also recommended one-time HCV
screening of adults in this birth cohort [6]. Because this
birth cohort overlaps with Vietnam-era veterans, we
sought to estimate the proportion of veterans seen at
the Atlanta VA Medical Center (AVAMC) who had ever
been screened for HCV infection by birth year.
Methods
We used an administrative database that contained the
date of birth, gender, and race of veterans seen as inpa-
tients or outpatients at the AVAMC between January 1,
2011 and December 31, 2011. All laboratory results were
obtained from the AVAMC and included HCV antibody
tests that were performed between 1992 and 2011 and
all available HCV RNA viral loads. For veterans with more
than one HCV antibody test, the HCV antibody status was
considered positive if any HCV antibody test was positive.
Any detectable value on either a quantitative or qualitative
RNA viral load was considered positive. Continuous
variables were compared using the Wilcoxon rank-sum
test. Odds ratios and 95% confidence intervals were esti-
mated using SAS version 9.2 (SAS institute, Cary, North
Carolina). A P value of ≤ .05 was considered statistically
significant. This study was approved by the Emory Univer-
sity Institutional Review Board and the VA Research and
Development Committee. Informed consent was waived
under a full HIPAA waiver.
Results
From 1992 through 2011, 91,240 HCV antibody tests were
completed on 67,539 veterans at the AVAMC (Figure 1).
Before enhanced VHA screening efforts began in 2001, a
median of 642 HCV antibody tests were done per year
(interquartile range [IQR]: 329 – 1,451); since 2001, a
median of 7,356 HCV antibody tests (IQR: 5,949 – 8,500)
were done per year (p = 0.002).
In 2011, 87,144 veterans were seen at the AVAMC;
data on age and sex was available in this database but in-
formation on race was largely missing (91% had a miss-
ing or unknown race) (Table 1). Over 50% of veterans
seen were between 50 and 69 years of age. While 89% of
Figure 1 Total number of hepatitis C antibody tests performed and percent of tests that are positive, by year — Atlanta VA Medical
Center, Atlanta, GA, USA. 1992 – 2011 (n = 91,240).
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all veterans seen in 2011 are male, when examined by
birth cohort, men made up 73% of those born after
1965. HCV antibody testing had ever been performed on
48% (41,556) of the veterans (Table 2). Of those who had
antibody testing, 49% (20,396) are African American, 37%
(15,343) are Caucasian, 1% (390) are “other” race (includes
Asian, Native Hawaiian, Pacific Islander, American Indian,
or Alaska Native); race is unknown in 13% (5,427) (data
not shown). HCV antibody was positive in 10% (4,107) of
those tested (Table 2). Of those with a positive HCV anti-
body, confirmatory RNA viral loads were performed in
96% (3,944). Chronic hepatitis C (i.e., a positive HCV anti-
body and a detectable RNA viral load) was identified in
73% (3,004).
When the veterans seen in 2011 were classified by birth
year, 27% were born before 1945, 54% were born during
1945 – 1965, and 19% were born after 1965. Among those
born before 1945, 35% (8,378) were ever tested for HCV
antibody; of those tested, 4% (335) were HCV antibody
positive, and 56% (189) of those with a positive HCV anti-
body had confirmed, chronic HCV infection (Table 2).
Among those born during 1945 – 1965, 54% (25,097) had
ever been tested; 15% (3,644) were HCV antibody positive,
and 76% (2,775) of those with a positive antibody had con-
firmed, chronic infection. In those born after 1965, 48%
(8,081) had been tested and 2% (128) were HCV antibody
positive; 31% (40) of those with a positive HCV antibody
had confirmed chronic HCV viremia. Over 97% with
chronic HCV viremia are male; among those born after
1965, 90% of those with chronic HCV viremia are male
(data not shown). Those born during 1945 – 1965 were
more likely to have a HCV antibody performed when
compared with those born in other years (54% vs. 41%,
odds ratio [OR] 1.70, 95% Confidence Interval [CI] 1.65-
1.74). Among veterans ever tested for HCV antibody,
those born during 1945 – 1965 were 6 times more likely
to have a positive HCV antibody (15% vs. 3%, OR 5.87,
95% CI 5.32-6.78) and 3 times more likely to have con-
firmed, chronic HCV infection (76% vs. 50%, OR 3.25,
95% CI 2.65-4.00).
Discussion
We found that nearly 50% of the veterans seen at the
AVAMC in 2011 had received HCV antibody screening.
Similarly, an analysis of National VHA HCV screening
practices found that 53% of veterans with at least one
outpatient visit at any VA clinic in 2011 had received
HCV screening [7]. Civilian primary care settings report
HCV screening rates of 1 – 8% [8-10] but interventions
designed to enhance HCV screening have been shown to
increase screening in high risk persons to 40% [5,10]. It
is likely that the enhanced HCV screening recommenda-
tions for veterans and the electronic clinical reminder
contributed to the higher HCV screening practices ob-
served in our population and other VHA settings.
After accounting for untested veterans, the overall
HCV prevalence among veterans seen at the AVAMC in
2011 is between 5% and 10%. While this estimate is com-
parable to published estimates at other VHA settings and
the national VA estimate [7,11-14], it is much higher than
Table 1 Gender (by birth cohort), age, and race of
veterans seen in 2011— Atlanta VA Medical Center
(n = 87,144)
No. %
Male, overall 77295 88.7
Male, born before 1945 23230 98.0
Male, born during 1945 − 1965 41834 89.6
Male, born after 1965 12231 72.9
Age, years
<30 3446 4.0
30-49 18981 21.8
50-69 46560 53.4
≥ 70 18157 20.8
Race
American Indian/Alaska Native 14 0.0
Asian 3 0.0
Black 7121 8.2
White 929 1.1
Unknown/Missing 78997 90.7
Hispanic 80 0.1
Table 2 Performance and positivity of hepatitis C antibody and RNA viral load tests for veterans seen in 2011, by birth
cohort - Atlanta VA Medical Center (n=87,144)
HCV Ab
performed
no.
HCV Ab
performed %
HCV Ab
positive no.
HCV Ab
positive %
Confirmatory
RNA
performed no.
Confirmatory
RNA %
RNA
positive no.
RNA positive
(chronic
disease) %*
Overall 41556 47.7% 4107 9.9% 3944 96.0% 3004 73.1%
< 1945 (N = 23702) 8378 35.3% 335 4.0% 305 91.0% 189 56.4%
1945 − 1965 (N = 46668) 25097 53.8% 3644 14.5% 3516 96.5% 2775 76.2%
> 1965 (N = 16774) 8081 48.2% 128 1.6% 123 96.1% 40 31.3%
Note: HCV – Hepatitis C virus, AB – Antibody, no. - Number.
*Percent is calculated using the HCV Ab positive number as the denominator.
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the estimated HCV prevalence of 1.6% obtained from a
national civilian survey [15]. Even among those born dur-
ing 1945 – 1965, the HCV tested prevalence is higher in
the veteran population (15%) compared with the civilian
population (3%) [15]. Although the higher HCV preva-
lence in veterans has been well described, reasons for the
higher burden are not fully understood and are likely
multifactorial.
Veterans born during 1945 – 1965 were more likely to
be screened for HCV, to have a positive HCV antibody,
and to develop chronic HCV infection. The VHA rec-
ommendation to perform HCV screening in Vietnam-
era veterans likely explains the higher HCV screening
seen in those born during 1945 – 1965. Our finding con-
firms the higher HCV prevalence in those born during
1945 – 1965, supporting the birth cohort screening rec-
ommendations of CDC and USPSTF. While it is not
fully understood why HCV prevalence is higher in this
birth cohort, it has been hypothesized that it reflects in-
cident HCV infections acquired through experimental
intravenous illicit drug use during the 1970’s and 1980’s
[16,17]. Additionally, higher HCV prevalence has been
observed in similar birth cohorts outside of the United
States, including in Scotland [18], England [19], and
Cameroon [20]. Lastly, we found that those born during
1945 – 1965 were at increased risk of having chronic
HCV infection (i.e. having a positive antibody and a
positive viral load). Among those born after 1965, only
31% of those with a positive HCV antibody also had a
positive viral load. There are two possible explanations
for having a positive HCV antibody and a negative viral
load; namely, a false positive HCV antibody or clearance
of HCV viremia. While it is surprising that relatively few
persons born after 1965 had evidence of chronic HCV
infection, it is notable that there are more females in this
cohort. Female sex has been associated with clearance of
HCV infection in prospective studies of acute HCV
[21-24]. While complex host and pathogen factors likely
influence the development of chronic HCV infection, fur-
ther exploration of the association between birth year and
the development of chronic HCV infection is warranted.
Confirmatory HCV RNA viral loads were performed
in 96% of the HCV antibody positive persons. This high
confirmatory testing rate was also seen in an analysis of
national VA data [7]. In contrast, surveillance for HCV
infections from eight civilian US sites found that con-
firmatory RNA viral loads were only performed in 50%
of positive HCV antibody tests [25]. By reflexively per-
forming HCV RNA viral load testing on positive HCV
antibody tests, the AVAMC testing practices are consist-
ent with the current CDC guidelines which recommend
RNA viral loads on all reactive HCV antibody tests [26].
Our analysis was limited to testing performed at the
AVAMC and did not include testing done at other VA
hospitals or testing done outside of VA system. However,
test results from additional sources would likely only in-
crease the screening estimates in our analysis. Because this
analysis used administrative databases, information on
HCV behavioral risk factors, medical comorbidities, and
the rationale used by providers for HCV screening is not
known. Information on race was missing for most vet-
erans seen at the AVAMC in 2011. Other administrative
databases from the AVAMC shows that 40% of veterans
seen in 2011 are African American race, 40% Caucasian,
and 2% “other” race; race was unknown in 18%. CDC and
USPSTF recommend HCV screening for all persons born
during 1945 – 1965, regardless of race. The veteran popu-
lation in our analysis is older than the general population
in the United States [http://www.census.gov/2010census/].
Lastly, because this analysis included a predominantly
male population our findings may not be applicable in
other settings.
Conclusions
The enhanced screening efforts undertaken at the AVAMC
in 2001 resulted in a significant increase in the annual
number of HCV antibody tests performed. The diagnosis of
chronic HCV infection allows for prevention interventions
such as alcohol counseling, vaccination against hepatitis A
and B, screening for advanced liver fibrosis, and referral for
antiviral therapy. HCV antiviral management is rapidly
evolving with the development of better tolerated and more
efficacious therapies [27]. Achieving a sustained virologic
response to antiviral therapy is known to significantly re-
duce the risk of liver failure [28], hepatocellular carcinoma
[29], liver-related and all-cause mortality [30,31], and re-
duces the risk of further HCV transmission.
We found that many veterans born during 1945 – 1965
had been screened for HCV infection at the AVAMC even
before the augmented CDC screening guidelines were
published in 2012. However, given the high prevalence of
disease in this birth cohort and the importance of HCV
detection, continued screening practices that target this
birth cohort are warranted.
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